foxo4 dri senolytic human trial 2024 2025 The costs and benefits of senotherapeutics for health Cellular Senescence in Kidney Diseases:
Description
Biophys J 94(8):31153125

4C, S3L, and S6)

The authors showed that this protocol was well tolerated and adequate for disease control, as the response lasted longer than that of other agents
10.1111/j.1469-7580.2009.01199.x [DOI] [PMC free article] [PubMed] [Google Scholar] Kang E

Kim y Y
